Board of Directors
Aisa Pharma’s Board of Directors provides governance, strategic oversight, and longterm vision as we advance our pipeline for patients with rare and serious diseases. Our directors bring complementary expertise in drug development, finance, company building, and partnering across the global biopharmaceutical industry.
Board Members
Our Board is composed of seasoned executives, investors, and scientific leaders with extensive experience guiding clinical-stage companies through key value inflection milestones.
Andrew Sternlicht MD, MA
CEO and Founder, Aisa Pharma
Andrew is board-certified anesthesiologist and businessman with 26 years of drug development experience at The Medicines Company, ActivBiotics and Dyax, and helped lead the development of an IV calcium channel blocker, Cleviprex®, as well as the development of Kalbitor®, a rare disease drug. Andrew has 10 patents and Aisa grew out of a personal need to find a treatment for his own Raynaud’s. On the faculty at Tufts Medical Center, Andrew received his BA and MA from Penn, his MD at Yale, and did postgraduate and residency training at Columbia, Harvard, and Cornell. In 1999 he started his first company, a health care services company called Hotelrecovery, Inc. He has been to both the FDA and Health Canada in different development programs. AISA’s origin came from a device he invented to keep patients warm during surgery as well as being the PI studies on N type calcium channel blocker treatments for certain pain conditions.
David M. Stack
David has a long and storied history in the pharmaceutical industry. After 17 years as the Chairman and Chief Executive Officer of Pacira Biosciences, Inc. Dave retired on January, 2, 2024. Mr. Stack was a managing director of MPM Capital from 2005 until 2017 and a managing partner of Stack Pharmaceuticals, Inc. since 1998. From 2001 to 2004, he was President and Chief Executive Officer of The Medicines Company. Previously, Mr. Stack was President and General Manager at Innovex, Inc. He was Vice President, Business Development/Marketing at Immunomedics from 1993 until 1995. Prior to that, he was with Hoffmann La Roche from 1981 until 1993, in various positions including therapeutic world leader for infectious disease, virology and oncology. Dave has served on over a dozen private and public company boards and as the chairman of Chiasma until its sale in 2021. Mr. Stack holds a B.S. in Pharmacy from Albany College of Pharmacy and a B.S. in Biology from Siena College. Dave was awarded the Ernst & Young Entrepreneur of the Year-2003 New Jersey Healthcare
Jason Fisherman, MD
Jason is an experienced venture investor, board member, and company founder, helping to build companies translating scientific innovation into product and business success. Over a multidecade career as managing director at the global private equity firm Advent International and Synthesis Capital, his portfolio of young companies has grown to launch important new medicines, biomedical products, and healthcare information services. He is currently co-founder and chief executive of an immunometabolism startup, Synkine Therapeutics. Before joining Advent in 1994, he spent over ten years in novel drug research and clinical development in biotech, academia, and the National Cancer Institute. Dr. Fisherman received a B.A. in Molecular Biophysics and Biochemistry from Yale, an M.D. from the University of Pennsylvania, and an M.B.A. from the Wharton School of the University of Pennsylvania. He is board-certified in internal medicine and medical oncology.
